Therapeutic effects of α-adrenergic receptor antagonists on benign prostatic hyperplasia: A network meta-analysis.
- Author:
Xian-Ping WANG
1
Author Information
- Publication Type:Journal Article
- Keywords: adverse event; alpha adrenergic receptor antagonist; network meta-analysis; benign prostatic hyperplasia
- MeSH: Adrenergic alpha-Antagonists; adverse effects; therapeutic use; Doxazosin; adverse effects; therapeutic use; Humans; Indoles; adverse effects; therapeutic use; Male; Network Meta-Analysis; Prostatic Hyperplasia; drug therapy; Quality of Life; Sexual Dysfunction, Physiological; chemically induced; Tamsulosin; adverse effects; therapeutic use
- From: National Journal of Andrology 2018;24(3):247-253
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the therapeutic effects of commonly used selective α-adrenergic receptor antagonists (α-ARA) on benign prostatic hyperplasia (BPH).
METHODSPubMed, Embase and CNKI databases were searched for the literature about selective α-ARAs for the treatment of BPH and the information was extracted on the common adverse reactions in the course of treatment. Multivariate meta-analysis was conducted to investigate the therapeutic effects of different α-ARAs.
RESULTSThe total rates of adverse effects of silodosin and tamsulosin were the highest, 51.9% and 34.0% respectively, with the highest incidences of headache (38.3%), weakness (23.6%) and dizziness (17.5%). Besides, tamsulosin ranked the first in inducing sexual dysfunction of the male patients with BPH (70.4%).
CONCLUSIONSDoxazosin is preferable as the first-choice treatment of BPH for its therapeutic effect and improvement of the patient's quality of life. Silodosin and tamsulosin, however, can be selectively used according to the patient's specific tolerance to different adverse effects.
